ABSTRACT
OBJECTIVE: To assess drug-drug interactions between cannabidiol (CBD) and phenobarbital (PB) when simultaneously administered to healthy dogs. ANIMALS: 9 healthy, purpose bred Beagles. PROCEDURES: A 3-phase prospective, randomized pharmacokinetic (PK) interaction study of CBD and PB was performed as follows: phase 1, CBD PK determination and evaluation of CBD tolerability by 3 single-dose CBD (5 mg/kg, 10 mg/kg, and 20 mg/kg) protocols followed by 2-week CBD dosing; phase 2, a single-dose, 3-way, crossover PK study of CBD (10 mg/kg), PB (4 mg/kg), or CBD (10 mg/kg) administration plus PB (4 mg/kg); and phase 3, evaluation of chronic PB (4 mg/kg, q 30 d) administration followed by single-dose CBD (10 mg/kg) PK study. RESULTS: Although there were variations in CBD PK variables in dogs receiving CBD alone or in conjunction with PB, significance differences in CBD PK variables were not found. No significant difference was observed in PB PK variables of dogs receiving PB alone or with CBD. During chronic CBD administration, mild gastrointestinal signs were observed in 5 dogs. At daily CBD doses of 10 to 20 mg/kg/d, hypoxia was observed in 5 dogs and increased serum alkaline phosphatase (ALP) activities (range, 301 to 978 U/L) was observed in 4 dogs. A significant increase in ALP activity was observed with chronic administration of CBD during phase 1 between day 0 and day 14. CONCLUSIONS AND CLINICAL RELEVANCE: No significant PK interactions were found between CBD and PB. Dose escalation of CBD or adjustment of PB in dogs is not recommended on the basis of findings of this study.
Subject(s)
Cannabidiol , Pharmaceutical Preparations , Animals , Dogs , Drug Interactions , Phenobarbital , Prospective StudiesABSTRACT
Flumazenil, a competitive GABAA receptor antagonist, is commonly used in rabbits to shorten sedation or postanesthetic recovery after benzodiazepine administration. However, no combined pharmacokinetic (PK) and pharmacodynamic (PD) data are available to guide its administration in this species. In a prospective, randomized, blinded, crossover study design, the efficacy of IV flumazenil (FLU; 0.05 mg/kg) or saline control (SAL; equal volume) to reverse the loss of righting reflex (LORR) induced by IV midazolam (1.2 mg/kg) was investigated in 15 New Zealand white rabbits (2.73 to 4.65 kg, 1 y old). Rabbits were instrumented with arterial (central auricular artery) and venous (marginal auricular vein) catheters. After baseline blood sampling, IV midazolam was injected (T0). Flumazenil or saline (FLU/SAL) was injected 30 s after LORR. Arterial blood samples were collected at 1 and 3 min after midazolam injection, and at 1, 3, 6, 10, 15, 21, 28, 36, 45 and 60 min after injection with flumazenil. Plasma samples for midazolam, 1-OH-midazolam and flumazenil were analyzed using high performance liquid chromatography-high-resolution mass spectrometry and the time to return of righting reflex (ReRR) was compared between groups (Wilcoxon test). FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively. ReRR was 25 times faster in rabbits treated with FLU (23 [8 to 44] s) compared with SAL (576 [130 to 1141] s; 95%CI [425 to 914 s]). Return of sedation (lateral recumbency) occurred in both groups (7/13 in FLU; 12/13 in SAL) with return of LORR in a few animals (4/13 in FLU; 7/13 in SAL) at 1540 [858 to 2328] s. In the population and anesthesia protocol studied, flumazenil quickly and reliably reversed sedation induced by midazolam injection. However, the potential return of sedation after flumazenil administration warrants careful monitoring in the recovery period.
Subject(s)
Flumazenil , Midazolam , Animals , Rabbits , Administration, Intravenous , Cross-Over Studies , Prospective StudiesABSTRACT
The efficacy of oral phenylbutazone [PBZ; 4.4 mg/kg body weight (BW), q12h], a non-selective non-steroidal anti-inflammatory drug (NSAID), and oral meloxicam (MXM; 0.6 mg/kg BW, q24h), a COX-2 selective NSAID, were evaluated in 2 experimental pain models in horses: the adjustable heart bar shoe (HBS) model, primarily representative of mechanical pain, and the lipopolysaccharide-induced synovitis (SYN) model, primarily representative of inflammatory pain. In the HBS model, PBZ reduced multiple indicators of pain compared with the placebo and MXM. Meloxicam did not reduce indicators of pain relative to the placebo. In the SYN model, MXM and PBZ reduced increases in carpal skin temperature compared to the placebo. Meloxicam reduced lameness scores and lameness-induced changes in head movement compared to the placebo and PBZ. Phenylbutazone reduced lameness-induced change in head movement compared to the placebo. Overall, PBZ was more effective than MXM at reducing pain in the HBS model, while MXM was more effective at reducing pain in the SYN model at the oral doses used.
Efficacité comparative du méloxicam oral et de la phénylbutazone dans deux modèles de douleur expérimentaux chez le cheval. L'efficacité de la phénylbutazone orale [PBZ; 4,4 mg/kg poids corporel (PC), q12h], d'un anti-inflammatoire non stéroïdien (AINS) non sélectif, et du méloxicam oral (MXM; 0,6 mg/kg PC, q24h), d'un AINS COX-2 sélectif, ont été évalués dans deux modèles de douleur expérimentaux chez des chevaux : le modèle du fer en cÅur ajustable (HBS), qui représente surtout la douleur mécanique, et le modèle de la synovite induite par le lipopolysaccharide (SYN), qui représente principalement la douleur inflammatoire. Dans le modèle HBS, PBZ a réduit plusieurs indicateurs de douleur comparativement au placebo et au MXM. Le méloxicam n'a pas réduit les indicateurs de douleur par rapport au placebo. Dans le modèle SYN, MXM et PBZ ont réduit les hausses de la température de la peau carpienne comparativement au placebo. Le méloxicam a réduit les scores de boiterie et les changements induits par la boiterie dans le mouvement de la tête comparativement au placebo et à PBZ. La phénylbutazone a réduit le changement du mouvement de la tête induit par la boiterie comparativement au placebo. Dans l'ensemble, PBZ était plus efficace que MXM pour réduire la douleur dans le modèle HBS, tandis que MXM était plus efficace pour réduire la douleur dans le modèle SYN aux doses orales utilisées.(Traduit par Isabelle Vallières).
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Lameness, Animal/drug therapy , Pain/veterinary , Phenylbutazone/administration & dosage , Synovitis/drug therapy , Thiazines/administration & dosage , Thiazoles/administration & dosage , Animals , Female , Horses , Lipopolysaccharides/administration & dosage , Male , Meloxicam , Pain/drug therapy , Skin Temperature/drug effects , Synovitis/veterinary , Treatment OutcomeABSTRACT
Meloxicam, a non-steroidal anti-inflammatory drug, is approved for use in horses in several countries, but an equine formulation is not available in North America. However, meloxicam is being used in an extra-label manner in horses in Canada. The purpose of this study, therefore, was to assess the bioequivalence of an approved oral meloxicam suspension (Metacam 15 mg/mL for horses; Boehringer Ingelheim Vetmedica GmBH, Ingelheim, Germany) from the European Union with human meloxicam tablets (Meloxicam 15 mg tablets; TEVA Canada, Toronto, Ontario) compounded with molasses to improve palatability and administration. The geometric mean ratios (GMR test/reference) and the 90% confidence intervals of the pivotal pharmacokinetic parameters (area under the curve and maximum concentration) were within the defined limits of 80% to 125% generally accepted for products to be considered bioequivalent. Therefore, use of human meloxicam tablets compounded with molasses would be expected to produce a similar clinical response in horses as the approved oral product from the European Union.
Pharmacocinétique et bioéquivalence de 2 formulations de posologie orale de méloxicam chez des chevaux adultes en santé. Le méloxicam, un médicament anti-inflammatoire non stéroïdien, est approuvé pour utilisation chez les chevaux dans plusieurs pays, mais une formulation équine n'est pas disponible en Amérique du Nord. Cependant, le méloxicam est utilisé en dérogation des directives de l'étiquette chez les chevaux du Canada. Par conséquent, le but de la présente étude était d'évaluer la bioéquivalence d'une suspension orale approuvée de méloxicam (Metacam 15 mg/ml pour les chevaux; Boehringer Ingelheim Vetmedica GmBH, Ingelheim, Allemagne) de l'Union européenne avec celle des comprimés de méloxicam pour les humains (comprimés de 15 mg de méloxicam; TEVA Canada, Toronto, Ontario) préparés avec de la mélasse pour améliorer la sapidité et l'administration. Les ratios géométriques moyens (test RGM/référence) et les intervalles de confiance de 90 % des paramètres phamacocinétiques clés (secteur sous la courbe et concentration maximale) se situaient dans les limites définies de 80 % à 125 % généralement attendues pour des produits considérés comme bioéquivalents. Par conséquent, l'utilisation des comprimés de méloxicam pour humains préparés avec de la mélasse devrait produire une réponse clinique semblable chez les chevaux à celle du produit oral approuvé provenant de l'Union européenne.(Traduit par Isabelle Vallières).
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Horses/metabolism , Thiazines/pharmacokinetics , Thiazoles/pharmacokinetics , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Area Under Curve , Cross-Over Studies , Dosage Forms , Female , Half-Life , Horses/blood , Male , Meloxicam , Therapeutic Equivalency , Thiazines/administration & dosage , Thiazines/chemistry , Thiazoles/administration & dosage , Thiazoles/chemistryABSTRACT
Genetic polymorphisms in enzymes controlling the formation and disposition of estrogens and their metabolites have been shown to influence breast cancer risk. Environmental and lifestyle factors may interact with estrogen metabolism polymorphisms to influence breast cancer risk. We studied the role of lifestyle factors and genetic polymorphisms in estrogen metabolism in women from Prince Edward Island (PEI), a small province of 135,000 people on the east coast of Canada. Women (207 cases; 621 controls) were matched on age, menopausal status, and family history of breast cancer. The predominant lifestyle risk factors previously reported to influence breast cancer risk such as body mass index (BMI), parity, and smoking had similar influences in the PEI population. Genetic polymorphisms in CYP17, GSTM1, and catechol-O-methyltransferase (COMT) were not associated with a general increase in breast cancer risk. However, the CYP17 A2/A2 genotype was only observed in women with estrogen receptor (ER) positive breast cancer and not in ER negative breast cancer. The increased risk associated with elevated BMI was only observed in women homozygous for the CYP17 and COMT reference alleles. Similarly, the increased risk associated with extended use of oral contraceptives (≥â15years), was only observed in women homozygous for the reference alleles of CYP17 and COMT. The GSTM1 homozygous gene deletion was associated with a significantly increased risk of breast cancer in postmenopausal women with a family history of breast cancer risk. These results suggest the polymorphic genes that control estrogen formation and disposition interact significantly with other risk factors to influence breast cancer risk.
Subject(s)
Breast Neoplasms/genetics , Catechol O-Methyltransferase/genetics , Genetic Predisposition to Disease , Glutathione Transferase/genetics , Life Style , Polymorphism, Genetic , Steroid 17-alpha-Hydroxylase/genetics , Body Mass Index , Case-Control Studies , Contraceptives, Oral , Female , Gene Deletion , Genotype , Homozygote , Humans , Logistic Models , Middle Aged , Prince Edward Island/epidemiology , Receptors, Estrogen , Risk AssessmentABSTRACT
In vitro evidence of the involvement of the endoplasmic reticulum (ER) during drug-induced renal toxicity is accumulating. ER stress and ER-mediated cell death markers have been reported after exposure of renal cells to model toxicants and nephrotoxic drugs in various in vitro models, but in vivo experiments with clinically relevant nephrotoxic compounds are lacking. In order to determine the relevance of the in vitro findings, markers of ER stress (XBP1 messenger RNA processing and protein expression; GRP78 and GRP94 upregulation) and ER-mediated cell death (caspase-12 and calpain activation) were examined in kidney tissue of rats exposed to nephrotoxic doses of cisplatin (CIS), gentamicin (GEN), and p-aminophenol (PAP), a nephrotoxic metabolite of acetaminophen. XBP1 signaling was observed with all three drugs and was associated with increased expression of GRP94 and GRP78 in GEN- and PAP-treated animals, but surprisingly not after CIS exposure. m-Calpain expression was increased after 7 days of CIS treatment, whereas it was decreased in PAP-treated rats. Caspase-12 cleavage products were increased after CIS, GEN, and PAP administration. The results of this study demonstrate that three clinically relevant nephrotoxic drugs are all associated with changes in markers of ER stress and ER-mediated cell death in vivo. Further investigation is warranted to determine the role of the ER, the calpain system, and caspase-12 in drug-induced renal cell death.
Subject(s)
Biomarkers/metabolism , Endoplasmic Reticulum/drug effects , Kidney Diseases/metabolism , Kidney/drug effects , Oxidative Stress/drug effects , Aminophenols/toxicity , Animals , Anti-Bacterial Agents/toxicity , Antineoplastic Agents/toxicity , Apoptosis , Basic-Leucine Zipper Transcription Factors/biosynthesis , Basic-Leucine Zipper Transcription Factors/genetics , Cisplatin/toxicity , DNA-Binding Proteins , Endoplasmic Reticulum/metabolism , Gene Expression/drug effects , Gene Expression Profiling , Gentamicins/toxicity , Heat-Shock Proteins/biosynthesis , Heat-Shock Proteins/genetics , Kidney/metabolism , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Diseases/pathology , Male , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Molecular Chaperones/biosynthesis , Molecular Chaperones/genetics , Mutagens/toxicity , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Regulatory Factor X Transcription Factors , Transcription Factors , Up-Regulation , X-Box Binding Protein 1ABSTRACT
p-Aminophenol (pAP, 225 mg/kg) administration to rats induced renal failure and has been associated with markers of endoplasmic reticulum (ER) stress, as well as calpain and caspase-12 activation in kidneys. To determine the importance of ER stress and calpain during pAP-induced nephrotoxicity, rats were pretreated with low, nontoxic, doses of ER stress inducers or with the selective calpain inhibitor PD150606 (3 mg/kg). Prior ER stress induced by tunicamycin and oxidized dithiothreitol did not result in protection against renal failure, but PD150606 administration was protective and decreased significantly the rise in creatinine and blood urea nitrogen observed after 24-h post-pAP administration. pAP-induced XBP1 upregulation was not modified by calpain inhibition, but a trend to lower GRP94 induction was determined, suggesting that pAP-induced ER stress was mostly calpain independent. In contrast, pAP-induced caspase-12 cleavage products were significantly decreased with PD150606 pretreatment, demonstrating that caspase-12 activation was calpain dependent. This study reveals the importance of calpain in pAP-induced renal failure. Further research with other nephrotoxicants needs to be performed to determine if calpain activation is a common feature of drug-induced renal failure.
Subject(s)
Aminophenols/toxicity , Calpain/antagonists & inhibitors , Endoplasmic Reticulum/drug effects , Kidney/drug effects , Mutagens/toxicity , Renal Insufficiency/prevention & control , Acrylates/pharmacology , Animals , Anti-Bacterial Agents/pharmacology , Blood Urea Nitrogen , Calpain/metabolism , Caspase 12/biosynthesis , Creatinine/blood , Disease Models, Animal , Dithiothreitol/pharmacology , Endoplasmic Reticulum/metabolism , Enzyme Inhibitors/pharmacology , Kidney/pathology , Kidney Tubules/drug effects , Kidney Tubules/pathology , Male , Necrosis/chemically induced , Necrosis/pathology , Oxidation-Reduction , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Renal Insufficiency/blood , Renal Insufficiency/chemically induced , Renal Insufficiency/pathology , Tunicamycin/pharmacologyABSTRACT
The cytoprotection of LLC-PK1 cells afforded by endoplasmic reticulum (ER) stress preconditioning suggests that the ER plays an important role during drug-induced renal toxicity. However, in vitro studies have been largely limited to LLC-PK1 cells and model toxins. Therefore, we tested the hypothesis that cytoprotection following ER stress preconditioning is a common property of renal cell lines (LLC-PK1 (pig), NRK-52E (rat), HEK293 (human), MDCK (dog)) and extends to clinically relevant nephrotoxins. ER stress inducers (tunicamycin, thapsigargin and oxidized dithiothreitol (DTTox)) resulted in a dose-dependent increase in GRP78 and GRP94 stress protein expression, but the magnitude of induction was cell line- and inducer-dependent. Toxicity of the model toxins iodoacetamide and tert-butylhydroperoxide was modified by preconditioning. DTTox was effective in decreasing the toxicity in all cell lines, but protection was variable with tunicamycin and thapsigargin. Toxicity of clinically relevant drugs (cisplatin, gentamicin, glyoxylate, cyclosporine A, p-aminophenol) was significantly decreased in cells preconditioned by tunicamycin or DTTox. These results demonstrate that ER stress preconditioning offers cytoprotection against clinically relevant nephrotoxins in renal cell lines from multiple species, although there were qualitative and quantitative differences between the cell lines. These results support the hypothesis that ER is involved in drug-induced renal toxicity.
Subject(s)
Endoplasmic Reticulum/physiology , Kidney Diseases/chemically induced , Kidney/pathology , Oxidative Stress/physiology , Animals , Dithiothreitol/pharmacology , Dogs , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum Chaperone BiP , Heat-Shock Proteins/metabolism , Humans , Iodoacetamide/toxicity , Kidney Diseases/metabolism , Kidney Diseases/pathology , L-Lactate Dehydrogenase/metabolism , LLC-PK1 Cells , Rats , Swine , Thapsigargin/pharmacology , Tunicamycin/pharmacologyABSTRACT
Calpains and endoplasmic reticulum (ER) stress have both been implicated in renal cell death following exposure to reactive chemical toxicants (RCTs). Therefore, we explored the link between ER stress, calpain, and cell death in renal cell injury due to model RCTs (iodoacetamide, menadione, tert-butyl hydroperoxide) and ER stress inducers (tunicamycin [TUN], thapsigargin [THAPS]). The calpain inhibitor, PD150606, significantly reduced the RCT and TUN-induced cell death in the renal cell line LLC-PK1, but not death induced by THAPS. ER stress was confirmed by the significant induction of GRP78 following exposure to RCTs and ER stress inducers. While GRP94 induction was observed following RCTs and TUN, it was not statistically significant because of variability. THAPS at 5 microM significantly induced GRP94, while 20 mmicroM caused a calpain-dependent cleavage of GRP94. Caspase-12 and m-calpain were variably induced and/or cleaved following exposure to all toxicants, supporting activation of these signaling pathways. Inhibition of calpain blocked the induction of GRP78 following exposure to RCTs suggesting that calpain was contributing to the observed ER stress following RCTs. In contrast, calpain inhibition did not block ER stress protein induction following exposure to nontoxic concentrations of TUN or THAPS, indicating that calpain inhibition did not block the ER stress protein induction pathways directly. These studies demonstrate a previously unappreciated link between calpain activation and ER stress-associated cell death in renal cells. While further studies are required to clarify the molecular events involved, these results confirm that calpain activation and the ER are important related players in chemically induced renal cell damage.
Subject(s)
Calpain/metabolism , Endoplasmic Reticulum/drug effects , Iodoacetamide/toxicity , tert-Butylhydroperoxide/toxicity , Acrylates/pharmacology , Animals , Calpain/antagonists & inhibitors , Cell Death/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Shape/drug effects , Cell Survival/drug effects , Chromatin/drug effects , Chromatin/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Endoplasmic Reticulum/metabolism , Glycoproteins/pharmacology , Heat-Shock Proteins/metabolism , Immunoblotting , L-Lactate Dehydrogenase/metabolism , LLC-PK1 Cells , Membrane Proteins/metabolism , Oligopeptides/pharmacology , Swine , Thapsigargin/toxicity , Time Factors , Tunicamycin/toxicity , Vitamin K 3/toxicityABSTRACT
Estrogen and its metabolites are believed to play important roles in breast cancer. The influence of genetic polymorphisms in the enzymes responsible for formation and disposition of estrogen on breast cancer risk may shed light on the importance of estrogen metabolites in this disease. However, for such studies to be valid, it is important to correctly identify the enzymes involved in estrogen bioactivation. Therefore, we assessed the human cytochrome P450-dependent oxidation of estrone using substrate concentrations that more closely approximate the maximum expected concentrations in breast tissue. The in vitro metabolism of estrone by recombinant human cytochrome P450 enzymes and human liver microsomes was studied. The formation of estrone metabolites (2-hydroxyestrone, 4-hydroxyestrone, and 16alpha-hydroxyestrone) was monitored by high-performance liquid chromatography. 2-Hydroxyestrone formation was catalyzed predominantly by CYP1A2, CYP1A1, and CYP1B1 enzymes; 4-hydroxyestrone formation was catalyzed predominantly by CYP1B1, CYP1A2, and CYP1A1 enzymes; and 16alpha-hydroxyestrone formation was catalyzed predominantly by CYP2C19, CYP1A1, and CYP3A5. This study confirms the important role of members of the CYP1 family in the 2-hydroxylation and 4-hydroxylation of estrone, but the enzymes identified as responsible for the 16alpha-hydroxylation of estrone are different from those previously identified. The relative importance of these enzymes in vivo would depend on the specific tissue expression of the enzymes. These enzymes are all known to be genetically variant in the human population, and additional studies to assess the role CYP1A2, CYP2C19, and CYP3A5 in breast cancer risk are indicated.
Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/enzymology , Cytochrome P-450 Enzyme System/metabolism , Estrone/metabolism , Breast Neoplasms/pathology , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP1A1/metabolism , Cytochrome P-450 CYP1A2/metabolism , Female , Humans , Hydroxylation , In Vitro Techniques , Microsomes, Liver/metabolism , Mixed Function Oxygenases/metabolism , Oxidation-Reduction , Sensitivity and Specificity , Tumor Cells, CulturedABSTRACT
OBJECTIVE: To evaluate concordance among veterinary pathologists in the assessment of histologic findings in the pars intermedia of pituitary gland sections from aged horses with mild signs suggestive of pituitary pars intermedia dysfunction (PPID). Sample Population-10 pituitary glands from aged horses. PROCEDURE: 7 pathologists were provided with signalment, clinical signs, and a single H&E-stained pituitary gland section from 10 aged horses with mild signs suggestive of PPID. Pathologists described histologic findings for each section and stated whether findings were consistent with PPID. Agreement among pathologists and with antemortem diagnostic test results was calculated. RESULTS: Overall, only fair agreement was found among the pathologists as to which horses had histologic findings consistent with disease (mean +/- SE kappa value, 0.34 +/- 0.069). Interpretation of individual sections varied, with minimal agreement (4 or 5/7 pathologists) for 5 of 10 sections evaluated. Postmortem assessment was in agreement with an antemortem endocrine diagnostic test result 79% of the time. CONCLUSIONS AND CLINICAL RELEVANCE: Validation of antemortem diagnostic testing for PPID in horses often relies on the results of postmortem histologic evaluation. The lack of consensus in histologic interpretation of pituitary glands from aged horses with mild clinical signs in our study indicates that postmortem histologic evaluation of pituitary glands is an inappropriate standard in validation of antemortem diagnostic tests for detection of early PPID. Caution should be used when interpreting diagnostic test results in horses in which early PPID is suspected.
Subject(s)
Horse Diseases/diagnosis , Horse Diseases/pathology , Pituitary Diseases/veterinary , Pituitary Gland/pathology , Age Factors , Animals , Dexamethasone/metabolism , Histological Techniques/veterinary , Horses , Pituitary Diseases/diagnosis , Pituitary Diseases/pathology , alpha-MSH/bloodABSTRACT
OBJECTIVE: To determine whether a deficiency in systemic or local (pars intermedia) antioxidant capacity is associated with pituitary pars intermedia oxidative stress and pituitary pars intermedia dysfunction (PPID) in horses. SAMPLE POPULATION: Blood samples from 20 horses with PPID and 20 healthy client-owned horses, archived paraffin-embedded adrenal gland and substantia nigra tissues from 20 horses, and pituitary gland tissue from 16 horses. PROCEDURES: Total glutathione, superoxide dismutase, and glutathione peroxidase activities were determined in RBCs. Accumulation of a systemic marker of oxidative stress (3-nitrotyrosine) was assessed in plasma and formalin-fixed, paraffin-embedded adrenal gland and substantia nigra tissues. Local antioxidants (total and manganese superoxide dismutase, glutathione peroxidase, and total glutathione) were measured in pars intermedia tissues. RESULTS: No significant differences existed in systemic antioxidant enzyme activity or accumulation of 3-nitrotyrosine between horses with PPID and control horses. In pituitary gland tissues, glutathione peroxidase activity was increased in horses with oxidative stress, whereas total glutathione concentration and superoxide dismutase activity remained unchanged. There was an age-associated decrease in manganese superoxide dismutase activity in the pars intermedia. CONCLUSIONS AND CLINICAL RELEVANCE: There was no evidence of systemic accumulation of oxidative stress markers or deficiencies in antioxidant capacity in horses with PPID, suggesting that these are unlikely to be major predisposing factors in the development of PPID. Manganese superoxide dismutase activity in the pars intermedia decreased significantly with increasing age. Role of an age-associated decrease in antioxidant capacity for the pars intermedia in the development of PPID in horses warrants further investigation.
Subject(s)
Antioxidants/metabolism , Horse Diseases/metabolism , Oxidative Stress/physiology , Pituitary Diseases/veterinary , Pituitary Gland/metabolism , Age Factors , Animals , Erythrocytes/metabolism , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Horses , Pituitary Diseases/metabolism , Superoxide Dismutase/metabolism , Tyrosine/analogs & derivatives , Tyrosine/blood , alpha-MSH/metabolismABSTRACT
Recent investigations have provided evidence to suggest systemic estrogen administration prevented or reversed the sympathoexcitation observed following middle cerebral artery occlusion (MCAO) in male rats. The present investigation sought to determine the role of estrogen injected directly into the parabrachial nucleus (PBN) on the MCAO-induced sympathoexcitation as well as the role of the rostral ventrolateral medulla (RVLM) in mediating the sympathoexcitatory response. Male Sprague-Dawley rats were anesthetized with sodium thiobutabarbitol (100 mg/kg) and were instrumented to continuously record blood pressure, heart rate and renal sympathetic nerve activity (RSNA). Following occlusion of the middle cerebral artery, there was a significant increase in RSNA (from 3.8 +/- 0.4 to 8.3 +/- 0.6 microV/s; P < 0.05) which was significantly attenuated by the prior bilateral injection of estrogen (0.5 microM in 200 nl) into the PBN. Pre-injection of lidocaine (5% in 200 nl) directly into the RVLM resulted in only a slight reduction in the magnitude of the MCAO-induced sympathoexcitation (P > 0.05). Extracellular electrophysiological recordings from RVLM neurons demonstrated that MCAO did not produce any significant change in neuronal activity over the experimental time course (P > 0.05). Also, bilateral injection of estrogen into the PBN prior to MCAO or sham conditions did not result in any significant change in RVLM neuronal activity. These results indicate that estrogen receptors in the PBN play a major role in modulating the sympathoexcitatory response from ischemic forebrain nuclei, and that the pathway from the PBN to sympathetic preganglionic nuclei may not involve a synapse in the RVLM.
Subject(s)
Estrogens/pharmacology , Infarction, Middle Cerebral Artery/physiopathology , Pons/physiology , Sympathetic Nervous System/physiopathology , Animals , Autonomic Nervous System/physiology , Electrodes, Implanted , Electrophysiology , Estrogens/administration & dosage , Male , Medulla Oblongata/physiology , Microdialysis , Microinjections , Neural Pathways/physiology , Rats , Rats, Sprague-Dawley , Sympathetic Nervous System/drug effectsABSTRACT
The endoplasmic reticulum (ER) is involved in an array of cellular functions that play important roles in xenobiotic toxicity. The ER contains the majority of cytochrome P450 enzymes involved in xenobiotic metabolism, as well as a number of conjugating enzymes. In addition to its role in drug bioactivation and detoxification, the ER can be a target for damage by reactive intermediates leading to cell death or immune-mediated toxicity. The ER contains a set of luminal proteins referred to as ER stress proteins (including GRP78, GRP94, protein disulfide isomerase, and calreticulin). These proteins help regulate protein processing and folding of membrane and secretory proteins in the ER, calcium homeostasis, and ER-associated apoptotic pathways. They are induced in response to ER stress. This review discusses the importance of the ER in molecular events leading to cell death following xenobiotic exposure. Data showing that the ER is important in both renal and hepatic toxicity will be discussed.
Subject(s)
Endoplasmic Reticulum/physiology , Xenobiotics/metabolism , Xenobiotics/toxicity , Animals , Endoplasmic Reticulum Chaperone BiP , HumansABSTRACT
Prior induction of an endoplasmic reticulum stress response results in protection against reactive cytotoxins in the LLC-PK1 cell line. The purpose of this investigation was to determine therefore if the endoplasmic reticulum was disrupted by iodoacetamide, tert-butylhydroperoxide or sulfamethoxazole hydroxylamine. Toxic concentrations of the three toxins caused a dramatic loss of GRP94 protein within 3-8h of exposure, while induction of GRP78 and calreticulin occurred at 8 and 24h following exposure. There was no evidence of cytosolic elevation of calcium and neither dantrolene nor xestospongin were able to block the cytotoxicity of IDAM and TBHP. Exposure to the toxins led to DNA degradation and cleavage of procaspase-12. There was only evidence of procaspase-3 cleavage after TBHP exposure. These results demonstrate that the ER is disrupted by the reactive cytotoxins examined in LLC-PK1cells and suggest that the cytoprotection against low to moderate concentrations of cytotoxins observed following endoplasmic reticulum stress protein induction is likely due to a mechanism other than maintenance of calcium homeostasis.
Subject(s)
Cytotoxins/toxicity , Endoplasmic Reticulum/drug effects , Iodoacetamide/toxicity , Sulfamethoxazole/analogs & derivatives , tert-Butylhydroperoxide/toxicity , Aniline Compounds , Animals , Calcium/metabolism , Cell Line , Cell Survival/drug effects , DNA Fragmentation , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum Chaperone BiP , Fluorescent Dyes , HSP70 Heat-Shock Proteins/metabolism , Heat-Shock Proteins/metabolism , Humans , L-Lactate Dehydrogenase/metabolism , LLC-PK1 Cells , Membrane Proteins/metabolism , Molecular Chaperones/metabolism , Sulfamethoxazole/toxicity , Swine , U937 Cells , XanthenesABSTRACT
The current investigation examined the effect of estrogen in the insular cortex (IC) on autonomic tone and cardiac baroreceptor reflex function and sought to determine if modulation of neurotransmission was responsible for mediating this effect. Experiments were performed in Inactin-anaesthetized, male Sprague-Dawley rats. Animals were instrumented to record blood pressure, heart rate, vagal parasympathetic and renal sympathetic nerve activities, as well as cardiac baroreflex sensitivity (BRS). Direct, bilateral injection of 17beta-estradiol (0.5 microM; 200 nl/side) into the IC resulted in a significant increase in sympathetic tone (from 10 +/- 4 to 24 +/- 3) with no significant change in blood pressure, heart rate, parasympathetic tone or BRS measured at 30 min post-injection. This estrogen-induced effect was completely blocked by the co-injection of estrogen with the estrogen receptor antagonist, ICI 182, 780 (20 microM; 200 nl/side). Co-injection of estrogen with a GABA(B), NMDA or non-NMDA receptor antagonists did not effect the estrogen-induced increase in sympathetic tone. Co-injection of a sub-threshold dose of estradiol (0.125 microM; 200 nl/side) with the GABA(A) receptor antagonist, (+)-bicuculline (0.025 microM; 200 nl/side), resulted in an additive response to increase sympathetic nerve activity. These results suggest that estrogen acts on estrogen receptors to modulate GABA(A)-receptor-mediated neurotransmission within the IC to modulate sympathetic tone.
Subject(s)
Cerebral Cortex/physiology , Estrogens/pharmacology , Sympathetic Nervous System/physiology , gamma-Aminobutyric Acid/physiology , Animals , Autonomic Nervous System/cytology , Autonomic Nervous System/drug effects , Baroreflex/drug effects , Cerebral Cortex/drug effects , Estrogens/administration & dosage , Heart/drug effects , Hemodynamics/drug effects , Kidney/drug effects , Kidney/innervation , Male , Microinjections , Neurons/drug effects , Phenylephrine/pharmacology , Rats , Rats, Sprague-Dawley , Sympathomimetics/pharmacology , Vagus Nerve/physiologyABSTRACT
BACKGROUND: Serum total alkaline phosphatase (AP) activity commonly is high in dogs receiving phenobarbital. Specific isoenzymes responsible for this increase are not well documented. OBJECTIVES: The purposes of this study were 1) to qualitatively and quantitatively describe serum AP isoenzymes in phenobarbital-treated dogs and 2) to monitor changes in serum AP isoenzyme activities associated with phenobarbital treatment over time. METHODS: Serum AP isoenzyme activities were determined in a cross-sectional study of 29 dogs receiving phenobarbital (duration of treatment 2 months to 6.5 years). Additionally, in a prospective study of 23 dogs, serum AP isoenzyme activities were determined before and 3 weeks, 6 months, and 12 months after the start of phenobarbital treatment. Isoenzyme activities were quantitatively determined using wheat germ lectin precipitation and levamisole inhibition, and qualitatively (ie, present or absent) evaluated using cellulose acetate affinity electrophoresis. RESULTS: In phenobarbital-treated dogs with high serum total AP activity in the cross-sectional study, the increase was due predominantly to increased activities of the corticosteroid-induced (C-AP) and liver (L-AP) isoenzymes. Prospectively, serum total AP and L-AP activities were significantly higher at 3 weeks, 6 months, and 12 months after the start of phenobarbital treatment compared with pretreatment values. Serum C-AP and bone isoenzyme (B-AP) activities were significantly higher after 6 and 12 months of treatment. B-AP accounted for only a small amount of the total AP activity. No unusual or previously unidentified AP isoenzymes were identified. CONCLUSIONS: Phenobarbital treatment was associated with increased C-AP and L-AP isoenzyme activities and with a minor increase in B-AP activity. No unique "phenobarbital-induced" isoenzyme was identified. Isoenzyme analysis does not appear to be useful for differentiating between high serum total AP due to phenobarbital therapy and other causes.
Subject(s)
Alkaline Phosphatase/blood , Anticonvulsants/adverse effects , Dog Diseases/drug therapy , Epilepsy/veterinary , Phenobarbital/adverse effects , Animals , Cross-Sectional Studies , Dog Diseases/enzymology , Dogs , Epilepsy/drug therapy , Epilepsy/enzymology , Isoenzymes/blood , Prospective StudiesABSTRACT
OBJECTIVE: To investigate effects of sample handling, storage, and collection time and season on plasma alpha-melanocyte-stimulating hormone (alpha-MSH) concentration in healthy equids. ANIMALS: 11 healthy Standardbreds and 13 healthy semiferal ponies. PROCEDURE: Plasma alpha-MSH concentration was measured by use of radioimmunoassay. Effects of delayed processing were accessed by comparing alpha-MSH concentrations in plasma immediately separated with that of plasma obtained from blood samples that were stored at 4 degrees C for 8 or 48 hours before plasma was separated. Effects of suboptimal handling were accessed by comparing alpha-MSH concentrations in plasma immediately stored at -80 degrees C with plasma that was stored at 25 degrees C for 24 hours, 4 degrees C for 48 hours or 7 days, and -20 degrees C for 30 days prior to freezing at -80 degrees C. Plasma alpha-MSH concentrations were compared among blood samples collected at 8:00 AM, 12 noon, and 4:00 PM. Plasma alpha-MSH concentrations were compared among blood samples collected in January, March, April, June, September, and November from horses and in September and May from ponies. RESULTS: Storage of blood samples at 4 degrees C for 48 hours before plasma was separated and storage of plasma samples at 4 degrees C for 7 days prior to freezing at -80 degrees C resulted in significant decreases in plasma alpha-MSH concentrations. A significantly greater plasma alpha-MSH concentration was found in September in ponies (11-fold) and horses (2-fold), compared with plasma alpha-MSH concentrations in spring. CONCLUSIONS AND CLINICAL RELEVANCE: Handling and storage conditions minimally affected plasma alpha-MSH concentrations. Seasonal variation in plasma alpha-MSH concentrations must be considered when evaluating pituitary pars intermedia dysfunction in equids.
Subject(s)
Horses/blood , Seasons , alpha-MSH/blood , Analysis of Variance , Animals , Radioimmunoassay , Specimen Handling , Time FactorsABSTRACT
The effect of oral treatment with natural or recombinant human interferon alpha (HIA) on inflammatory airway disease in young standardbreds was assessed in a double-blind, randomized clinical trial. A total of 34 horses with nasal discharge, excess mucus in the trachea, and a persistent cough of at least 2 weeks' duration that interfered with training completed the trial. Horses were rested for 1 week and received oral treatment with either a saline placebo, recombinant human interferon alpha (rHIA; 90 U/horse/day), or natural human interferon alpha (nHIA: 50 U/horse/day) for 5 days. There was a significant decline in nasal discharge and cough scores in all groups and the apparent response rate was similar. However, significantly fewer horses relapsed within 2 weeks once treatment was ceased when interferon rather than placebo was used (P = 0.012). Seventeen of 22 horses treated with rHIA or nHIA were cough-free 4 weeks after treatment, compared with only 4 of 12 after treatment with the placebo. Treatment with oral interferon is a useful adjunct to rest in standardbreds with inflammatory airway disease.
Subject(s)
Horse Diseases/drug therapy , Interferon Type I/therapeutic use , Respiratory Tract Diseases/veterinary , Administration, Oral , Animals , Bronchoalveolar Lavage Fluid/cytology , Double-Blind Method , Female , Horse Diseases/pathology , Horses , Interferon Type I/administration & dosage , Male , Recombinant Proteins , Respiratory Tract Diseases/drug therapy , Severity of Illness Index , Treatment OutcomeABSTRACT
The current investigation examined the role of estrogen in the insular cortex (IC) under both normal and ischemic conditions. Experiments were done in anaesthetized male Sprague-Dawley rats. The effect of systemic 17beta-estradiol (estrogen) administration on levels of amino acids and of endogenous estrogen obtained by microdialysis and its effect on neuronal activity of cells located in the insular cortex were measured in the absence of, and following permanent occlusion of, the right middle cerebral artery (MCA). In normal rats, intravenous (i.v.) injection of estrogen resulted in a significant increase (greater than 25 spikes/bin) in the spontaneous activity of neurons located within the insular cortex, while there was a significant decrease in gamma-aminobutyric acid (GABA) levels measured in IC dialysate. Middle cerebral artery occlusion (MCAO) resulted in a biphasic response consisting of a transient increase in the extracellular concentration of glutamate, aspartate, and GABA, followed by sustained elevations in glutamate and aspartate, but reduced GABA levels 4 h post-MCAO. MCAO also resulted in a significant increase in neuronal activity in the IC (from 28 +/- 9 to 120 +/- 88 spikes/bin). This MCAO-induced excitation was completely blocked following the prior intravenous administration of estrogen. Systemic estrogen administration also resulted in a delay in the progression and decrease in the final infarct volume by approximately 56%. Taken together, these results suggest that under normal conditions, estrogen excites neurons in the insular cortex by decreasing GABA release (disinhibition) and it plays a role in attenuating the MCAO-induced excitability and death of these neurons.